Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy : the Eastern Cooperative Oncology Group (ECOG) Results of Protocol E1293

摘要: The aim of this study was to evaluate the clinical efficacy and safety docetaxel (Taxotere) in patients with adenocarcinoma upper gastrointestinal tract previously untreated cytotoxic chemotherapy. Docetaxe1100 mg m−2 administered as a 1 hour intravenous (IV) infusion every 3 weeks 41 patients. Patients were premedicated prior each course dexamethasone, diphenhydramine cimetidine. Clinical response toxicity determined. Objective responses seen seven eligible (two complete [CRs] five partial [PRs], for an objective rate 17% (90% confidence interval [CI], 8% 30%). most common grade 4 neutropenia, which occurred 88% patients; 46% required dose reduction following episode neutropenic fever requiring antibiotic therapy. Additional have had reversible 3–4 toxicities including nausea, vomiting, stomatitis, diarrhea, fatigue peripheral neuropathy. Ten 1–3 hypersensitivity reactions. Alopecia has been majority Fluid retention observed Docetaxel on schedule is active agent adenocarcinomas tract. Further investigation drug should be conducted multi-drug combination programs.